Filter
91
Filtered Results: 91
Text search:
DNDi
Featured
Recommendations
10
New Publications
9
Language
Document type
Studies & Reports
32
No document type
18
Manuals
7
Guidelines
7
Strategic & Response Plan
7
Resource Platforms
5
Fact sheets
5
Videos
4
Brochures
2
Infographics
2
Training Material
1
Situation Updates
1
Countries / Regions
Global
10
Latin America and the Carribbean
8
Colombia
4
Kenya
2
Africa
2
West and Central Africa
2
East and Southern Africa
2
Brazil
2
Ethiopia
2
Asia
1
Congo, Democratic Republic of
1
South–East Asia Region
1
Southern Africa
1
Bangladesh
1
Uganda
1
Zambia
1
India
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
19
Clinical Guidelines
11
Pharmacy & Technologies
3
Public Health
1
Key Resources
1
Toolboxes
NTDs
59
HIV
6
Global Health Education
3
COVID-19
2
Pharmacy
2
AMR
2
TB
1
Planetary Health
1
Health Financing Toolbox
1
NCDs
1
The Leishmaniasis East Africa Platform (LEAP) was established to support the generation of scientific evidence for the development and distribution of new treatments for leishmaniasis in Eastern Africa.
Leishmaniasis is a climate-sensitive disease. Changes in temperature, rainfall, and humidity can have strong impacts on
the sandfly vector, altering their distribution and influencing their survival and population sizes. Increased temperatures shorten vector development time, reduce Leishmania para...
Mycetoma is a slow-growing bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care.
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...
Aprendiendo sobre el Chagas para mejorar el acceso al diagnóstico y
tratamiento de la enfermedad.
Guía de Líderes comunitaros
Accessed March, 2025
Cutaneous Leishmaniasis (CL) is a painful disease that exerts a serious toll on societies around the world that are afflicted by it. Although not life-threatening, the skin ulcers and scars it causes can lead to isolation and psychosocial pathologies due to social stigma, and its occurrence is often...
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...
Apuntes del Taller, Anexo
A Mini Review of Antiparasitic Agents explored between 2010-2021. Frontiers in Chemistry 9:771143
PROTOCOLO DE EVALUACIÓN DIAGNÓSTICA
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
PLoS Negl Trop Dis 15(8): e0009697. Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses t...
PLoS Neglected Tropical diseases August 16, 2021 https://doi.org/10.1371/journal.pntd.0009697
Chagas disease, also known as American trypanosomiasis, is a neglected tropical disease transmitted by triatomine insects, first identified in 1909. Chagas disease affects approximately 6–7 million peop...
Technology landscape
2nd edition
Meeting Report
27–30 June 2017 Manila, Philippines
